Published: April 06, 2010
Methuselah Foundation Launches NewOrgan Prize
WASHINGTON - (BUSINESS WIRE) - Today Methuselah Foundation launched the NewOrgan Prize, the
Foundation's new longevity prize specifically focused on advancing the
development of replacement tissues and organs for humans. Its goal is to
accelerate advances in regenerative medicine, which will become the
standard of care for replacing all tissue and organ systems in the body
within 20 years, according to the U.S. Department of Health and Human
Services.*
The first research team to construct a whole new complex organ (heart,
kidney, liver, lung, pancreas) made from a person's own cells âone that
is functionally equivalent and successfully transplantedâ will be
awarded the NewOrgan Prize. The goal of the Methuselah Foundation NewOrgan
Prize is to achieve this medical breakthrough within the next 10
years. Today's launch is a call to action for competitors, candidates
and contributors who want to participate in this crucial medical
challenge aimed at extending healthy human life.
"Based on our success in spurring medical advances with incentives
provided by the original Methuselah Mouse prize, we anticipate that over
$10 million will be raised by the time the NewOrgan Prize
criteria is met âand the prize presentedâ to the leading medical R&D
team," noted Methuselah Foundation CEO David Gobel. "At minimum, $1
million will be awarded to the research team that develops a whole new
human organ that is functional and successfully transplanted." Potential
competitors can reach Methuselah Foundation at info@mfoundation.org.
To date, Methuselah Foundation has secured commitments for $3.8 million
for prizes to be awarded for specific medical advances. To help support
those in need of replacement organs, Methuselah Foundation is also
establishing the NewOrgan Network, a wellness community powered by My
Bridge 4 Life. At the NewOrgan Network, those in need of replacement
organs can reach out to friends and family for personal support --- and
help drive scientific progress via the NewOrgan Prize. Prospective
members of the community can learn more and join the NewOrgan Network at http://www.neworgannetwork.com.
Since 2003, three Methuselah Foundation Mprizes have been presented to
researchers, including the Mprize given to Dr. David Sharp for the first
drug proven to extend healthy maximum lifespan in mice. All of these
prizes recognize breakthroughs that extend the lifespan of mice; they're
often referred to as the 'Methuselah Mouse' prizes. In addition to the
Mprize series, Methuselah Foundation also funds innovative new companies
that are creating breakthrough technologies, products, and solutions.
One example is Organovo <www.organovo.com>,
which has created the world's first commercial 3D Bio-Printer for
manufacturing human tissue and organs. The Foundation believes that this
kind of enabling technology will be key to achieving the goals of the NewOrgan
Prize.
Methuselah Foundation introduced the first Mprize in 2003 to accelerate
the development of revolutionary new life extension innovations.
Inspired by the 18th century Longitude Prize, the Mprizes are a series
of cash incentive prizes given to the first teams of doctors or
scientists to achieve specific life-extending medical goals. Studies
have shown that an incentive prize can generate activity worth 50 times
its value; that is, a $10 million incentive prize can spark $500 million
in scientific research and development. <www.mckinsey.com/App_Media/Reports/SSO/And_the_winner_is.pdf>.
The Obama Administration recently introduced a Strategy for American
Innovation, calling for agencies to increase their ability to
promote and harness innovation by using policy tools such as prizes and
challenges. See: http://www.whitehouse.gov/omb/assets/memoranda_2010/m10-11.pdf
Methuselah Foundation's scientific advisory board includes several
luminaries in the biological research and regenerative medicine field:
Anthony Atala, MD, W.H. Boyce Professor, Director of the Institute for
Regenerative Medicine, and chair of the Department of Urology at Wake
Forest University; Stephen F. Badylak, Professor, Department of Surgery
and Deputy Director, the McGowan Institute for Regenerative Medicine at
the University of Pittsburgh; Robert Cohen, CEO, Miromatrix; Gabor
Forgacs, biological physicist at the University of Missouri-Columbia;
Keith Murphy, CEO and President, Organovo; and Doris Taylor, Ph.D,
Director, Center for Cardiovascular Repair Medtronic Bakken, Professor
of Integrative Biology and Physiology, Professor of Medicine at the
University of Minnesota.
Methuselah Foundation is a non-profit medical charity dedicated to
extending healthy human life. Supported by the donations of individuals
and organizations, the programs of Methuselah Foundation include near,
mid and long term strategies that advance the mission of ending
age-related disease through awareness, education, scientific research
and direct community outreach. For more information please visit: www.methuselahfoundation.org.
*http://www.hhs.gov/reference/newfuture.shtml
Editors, please note: Broadcast quality video footage with additional
information about the Methuselah Foundation and the NewOrgan Prize can
be downloaded at: https://download.yousendit.com/RmNCOU1ha0RoeVpjR0E9PQ
or viewed on YouTube: http://www.youtube.com/watch?v=cvxiANklVIc

Methuselah Foundation
Susan DeVico, 510-339-1527 (media only)
SusanDV@aol.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News